Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%.
Here's what Shoenhaus could be thinking will catalyze a reversal for this stock.
In January, Recursion made an interesting decision regarding one of the assets it's developing in its fibrotic disease collaboration with .
Source Fool.com
Bayer AG Aktie
28,93 €
1,21 %
Mit 15 Buy-Einschätzungen und nur 1 Sell-Einschätzungen steht die Community der Aktie positiv gegenüber.
Das Kursziel von 50 € für Bayer AG weist auf eine Steigerung von über 50% gegenüber dem aktuellen Kurs von 28.93 € hin.
